Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor Positive, FGFR1/2/3-positive Breast Cancer: Phase I Clinical Trial Plus an Expansion Cohort

NCT04483505 is registered in ClinicalTrials.gov with Fundacion CRIS de Investigación para Vencer el Cáncer as lead sponsor.

NCT NCT04483505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04483505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor Positive, FGFR1/2/3-positive Breast Cancer: Phase I Clinical Trial Plus an Expansion Cohort
Lead sponsor
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase
Phase 1
Overall status
Completed
Start date
November 25, 2020
Completion date
April 4, 2023
Enrollment
9 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic, hormone receptor positive malignant neoplasm of breast